KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) EBT: 2018-2025

Historic EBT for Castle Biosciences (CSTL) over the last 8 years, with Sep 2025 value amounting to -$386,000.

  • Castle Biosciences' EBT fell 104.66% to -$386,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.9 million, marking a year-over-year decrease of 269.82%. This contributed to the annual value of $21.6 million for FY2024, which is 137.59% up from last year.
  • As of Q3 2025, Castle Biosciences' EBT stood at -$386,000, which was down 169.93% from -$143,000 recorded in Q2 2025.
  • Castle Biosciences' EBT's 5-year high stood at $8.3 million during Q3 2024, with a 5-year trough of -$29.2 million in Q1 2023.
  • For the 3-year period, Castle Biosciences' EBT averaged around -$5.7 million, with its median value being -$2.5 million (2024).
  • Its EBT has fluctuated over the past 5 years, first spiked by 410.31% in 2024, then plummeted by 955.48% in 2025.
  • Castle Biosciences' EBT (Quarterly) stood at -$15.2 million in 2021, then tumbled by 35.67% to -$20.6 million in 2022, then skyrocketed by 87.64% to -$2.5 million in 2023, then skyrocketed by 410.31% to $7.9 million in 2024, then tumbled by 104.66% to -$386,000 in 2025.
  • Its EBT was -$386,000 in Q3 2025, compared to -$143,000 in Q2 2025 and -$26.3 million in Q1 2025.